Literature DB >> 11021662

Lack of antibody production against Hanganutziu-Deicher (H-D) antigens with N-glycolylneuraminic acid in patients with porcine exposure history.

T Kobayashi1, I Yokoyama, A Suzuki, M Abe, S Hayashi, H Matsuda, K Morozumi, M E Breimer, L Rydberg, C G Groth, A Tibell, O Korsgren, H Takagi, A Nakao.   

Abstract

The significance of non-alphagalactosyl antigens remains unclear in pig-to-primate xenotransplantation. Hanganutziu-Deicher (H-D) antigens with terminal N-glycolylneuraminic acid (NeuGc) are widely expressed on endothelial cells of mammalian species, with the exception of humans. As baboons and monkeys also express H-D antigens, a pig-to-non-human primate experimental model cannot resolve the question of whether H-D antigens can elicit a potent humoral response in human recipients. The purpose of this study was to elucidate the clinical significance of H-D antigens by examining the sera from patients who have been previously exposed to porcine tissue. After the digestion of porcine aortic endothelial cells (PAEC) by neuraminidase, NeuGc and N-acetylneuraminic acid (NeuAc) were quantitated by HPLC. IgG and IgM antibody levels against H-D antigens were measured by NeuGc-GM3-coated ELISA plates in the sera of patients who had undergone ex vivo kidney perfusion 1 to 3 weeks and 2 years previously (n=2) or had been injected with fetal porcine islets 2 months previously (n= 10). HPLC determined that 9.7x 10(7) NeuAc and 6.3x 10(7) NeuGc residues per cell were released from PAEC by neuraminidase, while 25.7x 10(7) NeuAc and an undetectable level of NeuGc were released from human aortic endothelial cells (HAEC). No significant elevation of IgG or IgM antibody levels against NeuGc-GM3 was observed in sera from patients with a history of porcine exposure. Considering the active production of antibody against the foreign galactosyl antigens after pig-to-human xenotransplantation, some production of antibodies against the equally foreign H-D antigens would be expected, because large amounts of NeuGc terminated saccharides are present in the pig endothelial cell surface. However, no production of antibodies directed to H-D antigens could be found in patients exposed to porcine tissue. Further studies are warranted to explain why H-D antigens do not elicit a significant antibody production.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11021662     DOI: 10.1034/j.1399-3089.2000.00056.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  6 in total

1.  Brief report: a new profile of terminal N-acetyllactosamines glycans on pig red blood cells and different expression of alpha-galactose on Sika deer red blood cells and nucleated cells.

Authors:  Yingxia Tan; Feng Gong; Subo Li; Shouping Ji; Yanping Lu; Hongwei Gao; Hua Xu; Yangpei Zhang
Journal:  Glycoconj J       Date:  2010-04-27       Impact factor: 2.916

Review 2.  Recent investigations into pig antigen and anti-pig antibody expression.

Authors:  Guerard W Byrne; Christopher G A McGregor; Michael E Breimer
Journal:  Int J Surg       Date:  2015-08-22       Impact factor: 6.071

3.  Porcine sialoadhesin: a newly identified xenogeneic innate immune receptor.

Authors:  L G Brock; P L Delputte; J P Waldman; H J Nauwynck; M A Rees
Journal:  Am J Transplant       Date:  2012-09-07       Impact factor: 8.086

4.  Indigenous anti-ulcer activity of Musa sapientum on peptic ulcer.

Authors:  P Prabha; Thirunethiran Karpagam; B Varalakshmi; A Sohna Chandra Packiavathy
Journal:  Pharmacognosy Res       Date:  2011-10

Review 5.  The Structural Complexity and Animal Tissue Distribution of N-Glycolylneuraminic Acid (Neu5Gc)-Terminated Glycans. Implications for Their Immunogenicity in Clinical Xenografting.

Authors:  Michael E Breimer; Jan Holgersson
Journal:  Front Mol Biosci       Date:  2019-07-19

Review 6.  The Possible Role of Anti-Neu5Gc as an Obstacle in Xenotransplantation.

Authors:  Alfred Joseph Tector; Mathilde Mosser; Matthew Tector; Jean-Marie Bach
Journal:  Front Immunol       Date:  2020-04-15       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.